Prognostic value of various summary measures of prostate-specific antigen (PSA) kinetics for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy (TROPIC trial).

被引：0
|
作者：
Legrand, Catherine
Oudard, Stephane
Sartor, A. Oliver
De Bono, Johann Sebastian
Shen, Liji
Machiels, Jean-Pascal H.
机构：
[1] Catholic Univ Louvain, Inst Stat Biostat & Sci Actuarielles, B-1348 Louvain, Belgium
[2] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[3] Tulane Canc Ctr, New Orleans, LA USA
[4] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[5] Sanofi Aventis, Malvern, PA USA
[6] Catholic Univ Louvain, Ctr Canc, B-1200 Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16010
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Assessment of Angiogenic Factors and Hematopoietic Stem Cells and Their Relevance as Prognostic Factors for Overall Survival (OS) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients (pts): a Prospective Study
    Helley, D.
    Elaidi, R.
    Gachet, J.
    Kempf, E.
    Brizard, M.
    Levionnois, E.
    Banu, E.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S503 - S503
  • [42] PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY
    Stangl-Kremser, Judith
    Sun, Michael
    Ho, Benedict
    Thomas, Joseph
    Nauseef, Jones
    Osborne, Joseph
    Molina, Ana
    Sternberg, Cora
    Nanus, David
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2023, 209 : E384 - E385
  • [43] Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.
    Fizazi, Karim
    Heidenreich, Axel
    Daugaard, Gedske
    Bellmunt, Joaquim
    Germann, Nathalie
    Chetaille, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials.
    Goyal, Jatinder
    Huang, Peng
    Tyagi, Prachi
    Oh, Daniel
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES
    Corman, John
    Petrylak, Daniel P.
    Drake, Charles G.
    Pieczonka, Christopher M.
    Karsh, Lawrence I.
    Concepcion, Raoul S.
    Garcia, Jorge A.
    Dunshee, Curtis J.
    Van Mouwerik, Tim
    Tyler, Robert C.
    Chang, Nancy N.
    Quinn, David I.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E306 - E307
  • [46] Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naive metastatic castration-resistant prostate cancer (mCRPC)
    George, D. J.
    Ramaswamy, K.
    Yang, H.
    Liu, Q.
    Zhang, A.
    Greatsinger, A.
    Ivanova, J.
    Thompson, B.
    Emir, B.
    Hong, A.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S989 - S990
  • [47] A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)
    Halabi, Susan
    Luo, Bin
    Guo, Siyuan S.
    Knutson, Todd
    Lyman, Jacqueline
    Kobilka, Anna
    Beltran, Himisha
    Antonarakis, Emmanuel S.
    Rosenberg, Jonathan E.
    Galsky, Matt D.
    Ryan, Charles J.
    Kelly, William Kevin
    Small, Eric J.
    Morris, Michael J.
    Dehm, Scott M.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
    Uchimoto, Taizo
    Komura, Kazumasa
    Fukuokaya, Wataru
    Kimura, Takahiro
    Takahashi, Kazuhiro
    Nishimura, Kazuki
    Nakamori, Keita
    Fujiwara, Yuya
    Matsunaga, Tomohisa
    Tsutsumi, Takeshi
    Tsujino, Takuya
    Maenosono, Ryoichi
    Yoshikawa, Yuki
    Taniguchi, Kohei
    Tanaka, Tomohito
    Uehara, Hirofumi
    Ibuki, Naokazu
    Hirano, Hajime
    Nomi, Hayahito
    Takahara, Kiyoshi
    Inamoto, Teruo
    Egawa, Shin
    Azuma, Haruhito
    CANCERS, 2021, 13 (03) : 1 - 12
  • [49] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) who received prior androgen deprivation therapy (ADT) and reached low prostate-specific antigen (PSA) levels treated further with enzalutamide (ENZA): Post hoc analyses of ARCHES
    Petrylak, D. P.
    Azad, A. A.
    Szmulewitz, R. Z.
    Iguchi, T.
    Shore, N. D.
    Holzbeierlein, J.
    Alekseev, B.
    El-Chaar, N. N.
    Rosbrook, B.
    Ma, J.
    Zohren, F.
    Haas, G. P.
    Stenzl, A.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1183 - S1184
  • [50] Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1)
    Broyelle, Antonin
    Bimbai, Andre-Michel
    Carnot, Aurelien
    Pannier, Diane
    Makhloufi, Samira
    Ryckewaert, Thomas
    Penel, Nicolas
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345